Findings

What do systematic reviews say?

3,747 questions · 3,943 findings · 594 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 784 · 19.9%GRADE not reported 530 · 13.4%Very low 1,040 · 26.4%Low 981 · 24.9%Moderate 444 · 11.3%High 164 · 4.2%

Hyperbaric oxygen vs control without HBOT

Pain score change at 12 months · any person with osteoradionecrosis of the jaw or at risk of osteoradionecrosis of the jaw

1 finding from 1 review

Hyperbaric oxygen therapy for late radiation tissue injury 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 157 participants
Moderate

Hyperbaric oxygen vs control without HBOT

Complete resolution or significant improvement of osteoradionecrosis · any person with osteoradionecrosis of the jaw or at risk of osteoradionecrosis of the jaw

Hyperbaric oxygen therapy (HBOT) showed no clear difference in complete resolution or significant improvement of osteoradionecrosis compared with control without HBOT (low certainty).

1 finding from 1 review

Hyperbaric oxygen therapy for late radiation tissue injury 2023 · Cochrane Headline outcomes only
RR 1.26 [0.87, 1.82]
3 studies · 239 participants
Low

PFMT added to electrical stimulation vs pelvic floor muscle training (PFMT)

Cure: number of women with self‐reported continence · women with stress urinary incontinence

Electrical stimulation plus PFMT showed no clear difference in cure: number of women with self‐reported continence compared with PFMT (low certainty).

1 finding from 1 review

Electrical stimulation with non‐implanted devices for stress urinary incontinence in women 2017 · Cochrane Headline outcomes only
RR 0.76 [0.38, 1.52]
3 studies · 99 participants
Low

PFMT added to electrical stimulation vs pelvic floor muscle training (PFMT)

Improvement: number of women with self‐reported improvement in SUI (cured or improved) · women with stress urinary incontinence

Electrical stimulation plus PFMT showed no clear difference in improvement: number of women with self‐reported improvement in SUI… compared with PFMT (low certainty).

1 finding from 1 review

Electrical stimulation with non‐implanted devices for stress urinary incontinence in women 2017 · Cochrane Headline outcomes only
RR 1.1 [0.95, 1.28]
6 studies · 308 participants
Low

PFMT added to electrical stimulation vs pelvic floor muscle training (PFMT)

Incontinence‐specific quality of life · women with stress urinary incontinence

1 finding from 1 review

Electrical stimulation with non‐implanted devices for stress urinary incontinence in women 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 193 participants
Very low

PFMT added to electrical stimulation vs pelvic floor muscle training (PFMT)

Adverse effects · women with stress urinary incontinence

1 finding from 1 review

Electrical stimulation with non‐implanted devices for stress urinary incontinence in women 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 133 participants
Low

PFMT added to electrical stimulation vs pelvic floor muscle training (PFMT)

Cost‐effectiveness · women with stress urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Electrical stimulation with non‐implanted devices for stress urinary incontinence in women 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tricyclic antidepressants vs placebo

Efficacy for ADHD symptoms (parents using a rating scale) ‐ desipramine · Children and adolescents with ADHD

1 finding from 1 review

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 99 participants
Low

Tricyclic antidepressants vs placebo

Efficacy for ADHD symptoms (teachers using a rating scale) ‐ desipramine · Children and adolescents with ADHD

1 finding from 1 review

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents 2014 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 89 participants
Low

Tricyclic antidepressants vs placebo

CGI (response rate) ‐ desipramine and nortriptyline · Children and adolescents with ADHD

Tricyclic antidepressants (TCAs) may leads to higher CGI (response rate) ‐ desipramine and nortriptyline compared with placebo (low certainty).

1 finding from 1 review

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents 2014 · Cochrane Headline outcomes only
OR 18.5 [6.29, 54.39]
3 studies · 125 participants
Low

Tricyclic antidepressants vs placebo

Clinical global impression (response rate) ‐ desipramine · Children and adolescents with ADHD

Tricyclic antidepressants (TCAs) may leads to higher clinical global impression (response rate) ‐ desipramine compared with placebo (low certainty).

1 finding from 1 review

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents 2014 · Cochrane Headline outcomes only
OR 26.41 [7.41, 94.18]
2 studies · 103 participants
Low

Tricyclic antidepressants vs placebo

All‐cause treatment discontinuation ‐ desipramine · Children and adolescents with ADHD

1 finding from 1 review

Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents 2014 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 134 participants
Very low

Comprehensive geriatric assessment (CGA) vs usual care

Death (any cause) (median · older people at risk of poor health outcomes

Comprehensive Geriatric Assessment showed no clear difference in death Median compared with usual care (moderate certainty).

1 finding from 1 review

Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people 2022 · Cochrane Headline outcomes only
RR 0.88 [0.76, 1.02]
18 studies · 7151 participants
Moderate

Comprehensive geriatric assessment (CGA) vs usual care

Admission to a nursing home (end of · older people at risk of poor health outcomes

Comprehensive Geriatric Assessment showed no clear difference in nursing home admission Median compared with usual care (high certainty).

1 finding from 1 review

Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people 2022 · Cochrane Headline outcomes only
RR 0.93 [0.76, 1.14]
13 studies · 4206 participants
High

Comprehensive geriatric assessment (CGA) vs usual care

Unplanned admission to hospital · older people at risk of poor health outcomes

Comprehensive Geriatric Assessment may leads to lower unplanned hospital admission Median compared with usual care (low certainty).

1 finding from 1 review

Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people 2022 · Cochrane Headline outcomes only
RR 0.83 [0.7, 0.99]
6 studies · 1716 participants
Low

Comprehensive geriatric assessment (CGA) vs usual care

ED visits · older people at risk of poor health outcomes

It is very uncertain whether comprehensive Geriatric Assessment changes emergency department visits Median compared with usual care (very low certainty).

1 finding from 1 review

Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people 2022 · Cochrane Headline outcomes only
RR 0.65 [0.26, 1.59]
3 studies · 873 participants
Very low

Comprehensive geriatric assessment (CGA) vs usual care

Serious adverse events (falls) Median · older people at risk of poor health outcomes

It is very uncertain whether comprehensive Geriatric Assessment changes serious adverse events (falls) Median compared with usual care (very low certainty).

1 finding from 1 review

Comprehensive Geriatric Assessment for community‐dwelling, high‐risk, frail, older people 2022 · Cochrane Headline outcomes only
RR 0.82 [0.58, 1.17]
2 studies · 1380 participants
Very low

Uric acid lowering therapies (UAR) vs Placebo, no intervention or usual care (with or without placebo)

Death at 6 months · people with CKD

Uric acid lowering therapies (UAR) showed no clear difference in death at 6 months compared with placebo, no treatment or usual care (low certainty).

1 finding from 1 review

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease 2017 · Cochrane Headline outcomes only
RR 1.66 [0.61, 4.48]
2 studies · 498 participants
Low

Uric acid lowering therapies (UAR) vs Placebo, no intervention or usual care (with or without placebo)

Death at 2 years · people with CKD

Uric acid lowering therapies (UAR) showed no clear difference in death at 2 years compared with placebo, no treatment or usual care (low certainty).

1 finding from 1 review

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease 2017 · Cochrane Headline outcomes only
RR 0.13 [0.02, 1.06]
2 studies · 220 participants
Low

Uric acid lowering therapies (UAR) vs Placebo, no intervention or usual care (with or without placebo)

Dialysis · people with CKD

Uric acid lowering therapies (UAR) showed no clear difference in dialysis at 2 years compared with placebo, no treatment or usual care (low certainty).

1 finding from 1 review

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease 2017 · Cochrane Headline outcomes only
RR 0.4 [0.05, 3]
2 studies · 220 participants
Low